Uncategorized

Astellas Pharma Inc. announced positive topline results from the Phase 3b DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms due to menopause.

Reata Pharmaceuticals, Inc. announced that the United States Food and Drug Administration has approved the Prior Approval Supplement to update the drug substance specification for SKYCLARYS®, the first and only FDA approved drug for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

Spago Nanomedical AB announces that a preliminary analysis of data from the phase IIa clinical study SPAGOPIX-02 shows that SN132D has a good safety profile in patients with endometriosis.

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival.

Sihuan Pharmaceutical Holdings Group Ltd. together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Company, has received a drug registration approval from the National Medical Products Administration of China of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.

Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease.

Axsome Therapeutics, Inc. announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.

Kalos Medical Inc. announced on June 23rd that South Korea’s Ministry of Food and Drug Safety designated the company’s DENEX hypertension treatment system as an Innovative Medical Device, a designation that recognizes medical devices that significantly improve safety and efficacy compared to existing medical devices and treatments.

Verona Pharma plc, announces the American Journal of Respiratory and Critical Care Medicine has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease.

The vote approving Politan Capital’s nominees is “a clear mandate from shareholders that significant change is needed at Masimo,” said newly elected director Quentin Koffey.